Interní Med. 2006; 8(6): 288-291

Depression common with somatics disorders - tianeptin in primary care

prof. MUDr. Jaroslav Bouček CSc
Psychiatrická klinika FN a LF UP, Olomouc

Depression (D) is serious, chronic disease of the brain, affecting 10% of the population. At the same time full life prevalence is 17%. D is the disorder, which is combined with the lowest level of social position and physical performance as compared to diabetes, hypertension or arthritis. D requires continuous and supportive treatment, however it is often insufficiently diagnosed and treated. There is a big mortality combined with depression, additionally cognitive functions are affected as well as endocrine changes are present and immunological response is decreased. D occurs with big range of different somatic diseases, and diagnosing it improves patient’s health and life prognosis. Tianeptin (Coaxil) was described as effective antidepressive and anxiolytic agent, with very good tolerance and wide spectrum of indications.

Keywords: Key words: major deppresive episode, secundary deppresion, symptoms of depression, antidepressant, tianeptin, main indications of tianeptin.

Published: June 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bouček J. Depression common with somatics disorders - tianeptin in primary care. Interní Med. 2006;8(6):288-291.
Download citation

References

  1. Bouček J, Novák T, Holinková M. Our expirience with tianeptine in the treatment of depressive states. Homeostasis, 39, 1999; 6.
  2. Bouček J, Šmoldasová J, Horčičková E, Stárková L. Clinical experience with Tiapridal in the treatment of delirant states. Homeostasis 36, 1995; 4: 236-237.
  3. Bouček J, Stárková L, Šmoldasová J, Horčičková E, Tirayová L. Tiapridal v klinické praxi - první zkušenosti. Zpravodaj klinické farmakologie a farmacie, r. 9, 1995; 1-2: 24-26.
  4. Bouček J. Depresivní pacienti v ordinaci praktického lékaře. Buletin Sdružení praktických lékařů ČR, roč. 11, 2001; 1: 32-35.
  5. Bouček J, Breier P, Dohnal J. Účinnost a snášenlivost tianeptinu při léčbě depresivních poruch. Čes. a slov. Psychiatrie, r. 98, 2002; 8: 439.
  6. Costa e Silva JA. A double-blind study of tianeptine´s efficacy versus placebo in generalized enxiety disorders in nondepressed patients. Eur Psychiatry, 1994; (suppl 1): 14OS, abstract.
  7. Češková E, Pálenský V, Skotáková S: Současné možnosti farmakoterapie deprese. Čes. slov. Psychiatrie, 100, 2004; 3: 148-152.
  8. Dóci I, Shahpesandy HM. Depresie spojené so závislosťou od alkoholu a ich liečba. Psychiatrie, Praha, 2001; 5: 239-241.
  9. Faltus F. Současné možnosti antidepresivní terapie - antidepresiva. Remedia, 9, 1999; 1: 14-31.
  10. Favre JD, Guelfi-Sozzi C, Delalleau B, Lôo H. Tianeptine and alkohol dependence. Eur. Neuropsychopharmacology, 1997; 7 (Suppl.): 347-351. Go to original source... Go to PubMed...
  11. Höschl C, Libiger J, Švestka J. Psychiatrie. 2. vyd., Praha, Tigis 2004.
  12. Invernizzi G, Aguglia E, Bertolino A, et al. The efficacy and safety of tianeptine in the treatment of depressive disorder: results of a controlled double-blind multicentre study vs amitriptyline. Neuropsychobiology, 1994; 30: 85-93. Go to original source... Go to PubMed...
  13. Kořínková V, Kolibáš E, Novotný V. Význam vyššieho veku pre výber antidepresíva. Čs. Psychiat., 99, 2003; 6: 311-316.
  14. Kořínková V, Kolibáš E, Novotný V, Hunáková D. Liečba a profylaxia depresie vo vyššom veku. Čs. Psychiat., 93, 1997; 3: 12-18.
  15. Lôo H, Malka R, Defrance R, et al. Tianeptine and amitriptyline: controlled double-blind trial in depressed alcoholic patients. Neuropsychobiology, 1988; 19: 79-85. Go to original source... Go to PubMed...
  16. Lôo H, Saiz-Ruiz J, Costa e Silva JA, et al. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J. Affect Disord. 1999; 56: 109-118. Go to original source... Go to PubMed...
  17. Novotný V, Faltus F. First signs of improvement with tianeptine in the treatment of depression. An analysis of a double-blind study versus fluoxetine. Eur. Neuropsychopharm., 13, 2003; (Suppl. 4): 230. Go to original source...
  18. Novotný V, Faltus F. Tianeptine and fluoxetine in major depression: a 6-week randomised double-blind study. Hum. Psychopharmacol. Clin. Exp., 17, 2002: 299-303. Go to original source... Go to PubMed...
  19. Pálová E, Breznoščáková D, Sokoliová J, Moščovič P, Balcová D, Szokeová E. Vplyv depresie na kvalitu života u pacientov s kardiovaskulárnym ochorením - ročné sledovanie. Psychiatrie, 7, 2003, (Suppl. 1).
  20. Raboch J, Zvolský P, et al. Psychiatrie. Praha, Galén 2001.
  21. Švestka J, et al. Psychofarmaka v klinické praxi. Praha, Grada Publishing 1997.
  22. Vinař O. Volba antidepresiva podle pohlaví. Psychiatrie, 7, 2003, Suppl. 1.
  23. Vinař O. Serotonin, alkohol, SSRI a tianeptin. Jak se to rýmuje? Čes. a slov. Psychiat., 99, 2003; 8: 434-441.
  24. Vinař O. Tianeptine helps depressed patients resistant to reuptake inhibitors and/ or IMAO. Homeostasis, 39, 1999: 234-235.
  25. Waintraub L, Septien L, Azoulay P. Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine. European Neuropsychopharmacology, April 2000; S51.
  26. Waranabe Y, Gould E, Danniels DC. Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur. J. Pharmacol., 222, 1992: 157-162. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.